Apremilast

Beyoncé to be Honored with the iHeartRadio Innovator Award at the 2024 iHeartRadio Music Awards Airing Monday, April 1 on FOX

Retrieved on: 
Thursday, March 21, 2024
Entertainment, Other Entertainment, General Entertainment, Celebrity, Music, Events, Concerts, Apremilast, IHeartRadio, Tyla, Jelly roll, Doja Cat, AAA, Doechii, Green Day, Ice Spice, FOX, History, News, TLC, Pop Airplay, AC, Dolby Theatre, LIVE, Radio, Housing, Water, IHeartRadio Music Awards, Fox Entertainment Group, Hip hop music, Featherweight, SZA, R&B, Usher

iHeartMedia and FOX Entertainment today announced that Beyoncé will be honored with the iHeartRadio Innovator Award at the 2024 iHeartRadio Music Awards.

Key Points: 
  • iHeartMedia and FOX Entertainment today announced that Beyoncé will be honored with the iHeartRadio Innovator Award at the 2024 iHeartRadio Music Awards.
  • ET live / PT tape-delayed) on FOX and will also be heard on iHeartMedia radio stations nationwide and on the iHeartRadio app.
  • “I’m looking forward to hosting the 2024 iHeartRadio Music Awards and sharing the stage with some of the best in music,” said Ludacris.
  • For breaking news and exclusive iHeartRadio Music Awards content, visit iHeartRadio.com/awards or follow the social buzz on Twitter, Facebook and Instagram.

The 2024 iHeartRadio Music Awards, Airing Monday, April 1 on FOX Featuring Performances by Justin Timberlake, Green Day, TLC, Jelly Roll, Lainey Wilson, Tate McRae and More Live from Dolby Theatre in Los Angeles

Retrieved on: 
Monday, March 4, 2024
Entertainment, TV and Radio, Celebrity, Mobile Entertainment, Music, Events, Concerts, Featherweight, SZA, Tyla, FOX, Usher, News, Doechii, Dolby Theatre, Radio, Ice Spice, Doja Cat, History, IHeartRadio, Fox Entertainment Group, Label, Apremilast, TLC, Regional Mexican, Jelly roll, Billboard, LIVE, IHeartRadio Music Awards, Christmas

The event will air LIVE from Dolby Theatre in Los Angeles, Monday, April 1 (8:00-10:00 p.m.

Key Points: 
  • The event will air LIVE from Dolby Theatre in Los Angeles, Monday, April 1 (8:00-10:00 p.m.
  • The event also will be heard on iHeartMedia radio stations nationwide and on the iHeartRadio app.
  • Cher will receive the 2024 iHeartRadio Icon Award, honoring her unparalleled contributions to music and pop culture for over seven decades.
  • For breaking news and exclusive iHeartRadio Music Awards content, visit iHeartRadio.com/awards or follow the social buzz on Twitter, Facebook and Instagram.

Dermavant Appoints John Darden as New Head of Marketing

Retrieved on: 
Thursday, October 5, 2023
Marketing, Communications, Health, General Health, Pharmaceutical, Biotechnology, Apremilast, Therapy, Immunology, Skin, Psoriasis, Dermatology, Patient, Darden, Pharmaceutical industry, Management

Dermavant Sciences, a biopharmaceutical company dedicated to developing and commercializing innovative therapeutics in immuno-dermatology, today announced the appointment of John Darden as Vice President of Marketing.

Key Points: 
  • Dermavant Sciences, a biopharmaceutical company dedicated to developing and commercializing innovative therapeutics in immuno-dermatology, today announced the appointment of John Darden as Vice President of Marketing.
  • Darden brings more than 15 years of sales, marketing and market access experience in dermatology and immunology.
  • “I am proud to join a company of innovators and disruptors, with deep experience in dermatology and immunology,” said John Darden, Vice President of Marketing at Dermavant.
  • “We are thrilled to have John join Dermavant as our new VP of Marketing during a pivotal time in the company’s growth,” said Chris Chapman, Chief Commercial Officer at Dermavant.

Consecutive Use of TNF-Inhibitors for the Treatment of Psoriatic Arthritis at Lowest Point Recorded, as Use of Biologics with Alternate Mechanisms of Actions Continue to Grow, According to Spherix Global Insights

Retrieved on: 
Tuesday, October 3, 2023
Ixekizumab, Secukinumab, Amgen, NASA RealWorld-InWorld Engineering Design Challenge, MOA, TNF, Arthritis, Upadacitinib, Eli Lilly and Company, Risankizumab, Rheumatology, Patient, Psoriatic arthritis, Novartis, AbbVie, Algorithm, Physician, Need for Speed, Kwaku Amoa-Awuah, Safety, Guselkumab, Pharmaceutical industry, Apremilast

This results in a substantial patient population, with each physician handling an average of forty or more patients who switch their treatment on an annual basis.

Key Points: 
  • This results in a substantial patient population, with each physician handling an average of forty or more patients who switch their treatment on an annual basis.
  • Spherix Global Insights recently published its seventh annual Patient Chart Dynamix™: Triggers and Drivers in Psoriatic Arthritis, (previously RealWorld Dynamix: Switching in Psoriatic Arthritis).
  • Patients receiving TNFs are also provided an ample period of treatment in the first-line setting before considering a switch to an alternative therapy.
  • Patient Chart Dynamix™ is an independent, data-driven service unveiling real patient management patterns through rigorous analysis of large-scale patient chart audits.

AMGEN PRESENTS NEW RESEARCH ON OTEZLA® (APREMILAST) IN PSORIATIC ARTHRITIS AT EULAR 2023

Retrieved on: 
Tuesday, May 30, 2023
Apremilast, Inflammation, AMGN, Amgen, Psoriatic arthritis, University, Arthritis, University of Copenhagen, Ligament, Synovitis, Clinical trial, Finger, HDL, Research, Congress, MRI, BME, Magnetic resonance imaging, HIV disease progression rates, Poster, European, Rigshospitalet, LDL, Tenosynovitis, Joint, Global Medical Device Nomenclature, Body mass index, EULAR, All India Mahila Congress, Tendon, Glycated hemoglobin, Bone erosion, Pharmaceutical industry, Medical imaging, Silviculture, Hand, Rheumatology, Patient, MOSAIC

THOUSAND OAKS, Calif., May 30, 2023 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced new research examining the use of Otezla® (apremilast) in psoriatic arthritis, including the Phase 4 MOSAIC study and an exploratory analysis of cardiometabolic risk factors, which are commonly elevated in patients with psoriatic disease. The findings will be presented at the 2023 European Congress of Rheumatology (EULAR), taking place May 31-June 3 in Milan, Italy.

Key Points: 
  • The findings will be presented at the 2023 European Congress of Rheumatology (EULAR), taking place May 31-June 3 in Milan, Italy.
  • "Research presented at EULAR sheds new light on psoriatic arthritis and the role of our oral medication Otezla," said Ponda Motsepe-Ditshego, vice president, Global Medical at Amgen.
  • MOSAIC evaluated Otezla's effect on joint inflammation and structural progression of psoriatic arthritis measured by MRI.
  • "The results of this study are encouraging, as they provide important insights about Otezla treatment and its efficacy on both clinical and inflammatory manifestations of psoriatic arthritis."

Soligenix Enters into Exclusive Option Agreement with Silk Road Therapeutics for Rights to Topical Pentoxifylline Designed to Treat Behçet's Disease

Retrieved on: 
Monday, May 1, 2023
Apremilast, Mouth, Adalimumab, Doctor of Philosophy, Pain, Colchicine, Patient, Physician, PTX, Ulcer, POC, FDA, Therapy, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Food, Pharmaceutical industry, Pentoxifylline

PRINCETON, N.J., May 1, 2023 /PRNewswire/ -- Soligenix, Inc. (Nasdaq: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an unmet medical need, today announced that it has entered into an exclusive option agreement with Silk Road Therapeutics, a privately-held company. The option agreement grants the Company the right to acquire a novel topical formulation of Pentoxifylline (PTX), a non-biological anti-TNF-alpha inhibitor, for the treatment of mucocutaneous ulcers in patient's suffering from Behçet's Disease (BD). BD is a rare multisystem inflammatory vasculitis with no cure, characterized by debilitating recurrent ulcers in the oral mucosa (95%), skin/genitalia (50%), and eye compartment (15%). An orphan disease and area of unmet medical need affecting approximately 18,000 people in the United States (U.S.) and 80,000 in Europe, there are as many as 1,000,000 people worldwide living with this painful and life altering disease.  Terms of the deal were not disclosed.

Key Points: 
  • The option agreement grants the Company the right to acquire a novel topical formulation of Pentoxifylline (PTX), a non-biological anti-TNF-alpha inhibitor, for the treatment of mucocutaneous ulcers in patient's suffering from Behçet's Disease (BD).
  • BD is a rare multisystem inflammatory vasculitis with no cure, characterized by debilitating recurrent ulcers in the oral mucosa (95%), skin/genitalia (50%), and eye compartment (15%).
  • This trial enrolled patients with BD randomized to standard of care colchicine therapy (n=21) or colchicine plus topical PTX (n=18).
  • No serious adverse events were reported, consistent with the systemic use of PTX in the published literature.

AMGEN WINS PATENT APPEAL ON OTEZLA® (APREMILAST)

Retrieved on: 
Wednesday, April 19, 2023
Apremilast, AMGN, Patent, Amgen, United States Court of Appeals for the Federal Circuit, Judgement, Psoriasis, Teva Pharmaceuticals USA, Inc. v. Sandoz, Inc., Light, District court, Patient, Zydus Lifesciences, Douglas v. U.S. District Court ex rel Talk America, Generic drug, Novartis

THOUSAND OAKS, Calif., April 19, 2023 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced that the U.S. Court of Appeals for the Federal Circuit has affirmed the judgment of the U.S. District Court for the District of New Jersey in a patent infringement lawsuit against Sandoz Inc. ("Sandoz") and Zydus Pharmaceuticals (USA), Inc. ("Zydus"). Today's decision affirms the permanent injunction entered by the district court prohibiting Sandoz and Zydus from making, using, selling, offering to sell, or importing each of their generic versions of Otezla until February 2028.

Key Points: 
  • Three of Amgen's patents were the subject of the appeal.
  • The appellate court upheld the validity of U.S. Patent No.
  • 7,427,638, which claims pharmaceutical compositions of apremilast, and U.S. Patent No.
  • Before trial, both Sandoz and Zydus acknowledged that their generic versions of Otezla infringe the asserted claims of U.S. Patent No.

Bristol Myers Squibb Receives European Commission Approval of Sotyktu (deucravacitinib), a Once-Daily Oral Treatment for Adults With Moderate-to-Severe Plaque Psoriasis

Retrieved on: 
Tuesday, March 28, 2023
Science, Other Science, Biotechnology, Research, Pharmaceutical, General Health, Health, Clinical Trials, Apremilast, Bristol Myers Squibb, University, Civil service commission, Infection, Psoriasis, Lower respiratory tract infection, Doctor of Philosophy, BMY, Dermatology, Incidence, PSO, MD, Patient, Physician, TYK2, Common, NYSE, LTE, European Commission, Pharmaceutical industry, Deucravacitinib

The POETYK study program demonstrated a consistent safety profile in patients through three years of continuous treatment.

Key Points: 
  • The POETYK study program demonstrated a consistent safety profile in patients through three years of continuous treatment.
  • “Today’s approval is a landmark achievement as patients across Europe with moderate-to-severe plaque psoriasis will now have the opportunity to be treated with Sotyktu, the first once-daily oral option to provide significant symptom relief,” said Samit Hirawat , MD, chief medical officer, Bristol Myers Squibb.
  • Up to 90% of patients with psoriasis have psoriasis vulgaris, or plaque psoriasis, which is characterized by distinct round or oval plaques typically covered by silvery-white scales.
  • The majority of infections were non-serious and mild to moderate in severity and did not lead to the discontinuation of Sotyktu.

Bristol Myers Squibb Announces Positive CHMP Opinion for Once-Daily Sotyktu (deucravacitinib) as a Treatment for Adults With Moderate-to-Severe Plaque Psoriasis

Retrieved on: 
Friday, January 27, 2023
Biotechnology, Pharmaceutical, Health, Clinical Trials, Ministry of Health, Bristol Myers Squibb, TYK2, European Commission, Journal, CHMP, Light, Apremilast, NYSE, Lower respiratory tract infection, Civil service commission, Patient, Face, Committee, Skin, Folliculitis, Food, Ministry, BMY, Committee for Medicinal Products for Human Use, European Medicines Agency, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, American Academy, FDA, Journal of the American Academy of Dermatology, Ministry of Health, Labour and Welfare, Quality of life, Psoriasis, European, PSO, MD, Pharmaceutical industry, Deucravacitinib, EU

Bristol Myers Squibb (NYSE: BMY) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency has recommended the approval of Sotyktu (deucravacitinib) for the treatment of adults with moderate-to-severe plaque psoriasis.

Key Points: 
  • Bristol Myers Squibb (NYSE: BMY) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency has recommended the approval of Sotyktu (deucravacitinib) for the treatment of adults with moderate-to-severe plaque psoriasis.
  • Sotyktu, an oral medication taken once-daily, is a first-in-class, selective, allosteric tyrosine kinase 2 (TYK2) inhibitor for the treatment of moderate-to-severe plaque psoriasis in adults who are candidates for systemic therapy.
  • The CHMP recommendation will now be reviewed by the European Commission, which has the authority to approve medicines for the European Union (EU).
  • Bristol Myers Squibb thanks the patients and investigators involved in the POETYK PSO clinical trial program.

Pharmascience Canada launches pms-APREMILAST, a generic drug with multiple indications

Retrieved on: 
Tuesday, January 17, 2023
Methotrexate, Tablet, Safety, Psoriasis, Apremilast, Patient, Light, DMARD, Pharmaceutical industry

MONTREAL, Jan. 17, 2023 /CNW Telbec/ - Pharmascience Canada is pleased to launch pms-APREMILAST, only in 30 mg tablets in Canada.

Key Points: 
  • MONTREAL, Jan. 17, 2023 /CNW Telbec/ - Pharmascience Canada is pleased to launch pms-APREMILAST, only in 30 mg tablets in Canada.
  • This is a generic equivalent of the product Otezla®.
  • "Pharmascience is pleased to add the first generic equivalent of Otezla® to our product portfolio.
  • As Canada's largest drug manufacturer, we remain committed to providing patients with a safe and cost-effective option for the treatment of their condition"- Mike Dutton, Vice President, and General Manager of Pharmascience Canada.